Market capitalization | $5.70m |
Enterprise Value | $2.78m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.19 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-24.60m |
Free Cash Flow (TTM) Free Cash Flow | $-23.28m |
Cash position | $7.75m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Aptevo Therapeutics Inc:
1 Analyst has issued a forecast Aptevo Therapeutics Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -24 -24 |
18%
18%
|
EBIT (Operating Income) EBIT | -25 -25 |
18%
18%
|
Net Profit | -24 -24 |
47%
47%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics to improve patients lives. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.
Head office | United States |
CEO | Marvin White |
Employees | 40 |
Founded | 2016 |
Website | www.aptevotherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.